Venus MedTech (HangZhou) Inc. is located in Hangzhou National High-tech Industrial Development Zone (Binjiang), with its products positioned in the development and industrialization of international advanced interventional artificial cardiac valve system, filling up the blank in China. Interventional artificial aortic valve products researched and developed by the company takes the lead in finishing clinical tests in China. In reference to the development and promotion conditions of coronary stents at home and abroad, interventional artificial cardiac valve, as a revolutionary treatment means, has been increasingly recognized by experts, and will take on an explosible increase of clinical needs in the foreseeable next few years.

Senju Pharmaceutical Beijing Co. Ltd., part of Senju Pharmaceutical Co., Ltd., is a company headquartered in Beijing, China, that manufactures and distributes pharmaceuticals.

Emulate, Inc. owns and operates Organs-on-Chips platform which acts as an automated human bioemulation platform for mimicking true human physiology. The firm's product responses to medicines, chemicals, and diseases can be predicted. The company was founded by James Coon, Donald Ingber and Geraldine Hamilton in July 2014 and is headquartered in Cambridge, MA.

Kinoshita KK engages in the wedding business and Funeral business. The company was founded in 1900 and is headquartered in Kurume, Japan.

CBR, Inc., part of Dufry AG, is a company headquartered in Minneapolis, MN, that designs, develops, and operates airport specialty retail stores. On December 17, 2007 Autogrill SpA, now a subsidiary of Dufry AG acquired CBR, Inc. for $23 million.

Cornell provides education about the earth and atmospheric sciences. They offer summer and winter sessions. Their students contact them through phone and email services.

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development, shares in the cost and risk of clinical development, and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Xiamen Bosay Gene Transcription Technology Co., Ltd., established on 2002-01-28, Business scope includes general items:Natural science research and experimental development;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;R&D and application of cell technology;Development of Human Gene Diagnosis and Therapy Technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology intermediary service;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals);Cosmetics Wholesale;Cosmetics Retail;Personal Hygiene Sales;Non-residential real estate leases.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Jiangsu Qi's Biotechnology Co., Ltd., established on 2009-12-16, Business scope includes biopharmaceutical reagents,Research on New Drug Diagnostic Reagents,to develop,Technical Services;R&D and application of cell technology and cell products,technical consulting,technology transfer,Technical Services;Stem Cell and Immune Cell Banking Services;biopharmaceuticals(Does not contain dangerous goods)promotion of;Self-operated and agent import and export business of various commodities and technologies,Except for commodities and technologies that are restricted by the state to be operated by enterprises or prohibited from import and export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shenyang Cell Therapy Engineering Technology R&D Center Co., Ltd., established on 2016-06-20, Business scope includes stem cells,R&D and application services of immune cell storage and preparation technology;cord blood storage,Biobank construction;Stem Cell Pharmaceutical Preparations,Targeted immune cell therapy technology research and development and application services;cell detection,Genetic testing technology research and development and testing services;Human Tissue Engineering Technology,cell therapy technology,Cosmetic Technology,Laboratory Equipment Technology,Computer software technology research and development,Technical Services,technical consulting,technology transfer;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval);medical instruments,cosmetic,Health products,chemical reagent(Hazardous and precursor chemicals excluded)Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Guangzhou Saliai Stemcell Science & Technology Co., Ltd. engages in the provision of stem cell storage, health supplements, biological products, and related health management services. It involves in the production of regenerative medicine devices, medical nutrition supplements, and biological & medical cosmetic products. It operates a research and development platform which includes life bank, health management center, medical center, and medical cell center. The company was founded by Hai Jia Chen and Ming Jia Chen on July 7, 2009 and is headquartered in Guangzhou, China.

Jiangsu Aierkang Biomedical Technology Co., Ltd., established on 2015-10-30, Business scope includes research and development of biochemical products,Production,Sales;Immunology and Molecular Diagnostic Technology,cell therapy technology,biomedicine,Research and Development of Biomaterials,technology transfer,technical consulting;Pharmaceutical Intermediates,Production of test reagents,Sales;one,Production and sales of Class II medical devices;Self-operated and agent import and export of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shijiazhuang Yiling Pharmaceutical develops, produces, and sells patent medicines. The product portfolio includes traditional medicine, health care products, western formulations, and TCM slices, among others. They supply, introduce advanced equipment and pharmaceutical technology both domestically and internationally, and develop a quality control system.

Guangdong Qianhui Biotechnology Co., Ltd., established on 2011-03-22, Business scope includes general business items:Biomedical Technology Development,Technical Services,technical consulting,technology transfer.,The licensing program is:none

Shanghai Ruilu Biotechnology Co., Ltd., established on 2014-12-30, The scope of business includes engaging in technology development in the field of biotechnology,technology transfer,technical consulting,Technical Services,Class I medical device,Chemical Products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),Daily necessities,Stationery,Electrical Equipment,Green facilities,hardware products,Instrumentation,electronic product,computer,Sales of software and auxiliary equipment,e-commerce(Not allowed to engage in value-added telecommunications,Financial services),translation service,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Provides research and development on medical sciences and pharmacy

The China-Japan Friendship Hospital (Chinese: 中日友好医院) was established through the cooperation of the Chinese and Japanese governments during the 1980s. The hospital has been directly affiliated with China's Ministry of Health since its first day of operation, October 23, 1984. The hospital is located on East Yinghuayuan Street, Chaoyang District, Beijing. The hospital covers 9.7 hectares, with floorspace of facilities measuring 180,000 square meters. Within the hospital, there are 1,500 beds, 58 departments, as well as a clinical research and education center. The hospital has intensive care and treatment of severe diseases as a primary focus and integrative eastern-western medicinal therapy as an additional area of expertise. The hospital often attends to the health care of senior officials from over 100 countries and regions.